Zimmer Biomet (NYSE: ZBH) announced today that it received FDA 510(k) clearance for its Persona Revision SoluTion Femur.
The US Food and Drug Administration (FDA) has granted 510(k) clearance to Zimmer Biomet's new revision knee implant component ...
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of Persona® Revision SoluTionâ„¢ Femur, a ...
A Revision Knee Implant Alternative for Patients with Metal Sensitivities WARSAW, Ind., March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ...
New bone cement formulations designed for prosthesis fixation in arthroplasty and joint reconstruction procedures ...
March 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings ... clearance of Persona® Revision SoluTionâ„¢ Femur, a revision knee implant component offering an alternative for patients with ...
The Terminator actor teamed up with Zimmer Biomet to raise awareness about osteoarthritis, which affects more than 25 million ...
On Thursday, 13 March 2025, Zimmer Biomet Holdings Inc. (NYSE ... The product side of the equation, the implant is now something like 20% to 25% of the DRG, whereas ten, twenty years ago it ...
March 10, 2025 /PRNewswire/ -- Zimmer Biomet Holdings ... benefit from a shorter surgical time compared to the cemented implant. The Oxford Partial Knee Is not indicated for use in the lateral ...